AI assistant
Advanced Enzyme Technologies Limited — Earnings Release 2026
Aug 2, 2025
62369_rns_2025-08-02_f0e23b36-3674-45d1-871c-45433b1bd809.pdf
Earnings Release
Open in viewerOpens in your device viewer
August 02, 2025
BSE Limited P. J. Towers, Dalal Street, Mumbai- 400 001
National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai- 400 051
Scrip Code-540025
Trading Symbol-ADVENZYMES
Subject: Press Release Ref: ISIN: INE837H01020
Dear Sir/Madam,
Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is Press Release, titled "Quarterly Earnings Release” dated August 02, 2025.
This is for your information and for public at large.
Thanking you, Yours faithfully, For Advanced Enzyme Technologies Limited
SANJAY Digitally signed by SANJAY PRAKASH PRAKASH BASANTANI BASANTANI Date: 2025.08.02 15:00:56 +05'30' Sanjay Basantani Company Secretary and Head – Legal
Encl.: As above
==> picture [135 x 35] intentionally omitted <==
FOR IMMEDIATE RELEASE
Thane, India: Saturday, August 02, 2025
Advanced Enzyme Technologies Limited announces Financial Results for First Quarter ended June 2025
Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES; BSE: 540025), a leading specialty biotech company, with global leadership in the manufacturing of enzymes, today announced their unaudited financial results for first quarter ended June 2025.
CONSOLIDATED QUARTERLY FINANCIAL HIGHLIGHTS:
| (Amount in INR Mn.) | Q1 FY26 Q4 FY25 Q1 FY25 Change (Y-o-Y %) Change (Q-o-Q %) |
FY25 FY24 Change (%) |
|---|---|---|
| Revenue EBITDA EBITDA Margin (%) PAT PAT Margin (%) EPS |
1,859 1,672 1,545 20% 11% 564 456 512 10% 24% 30% 27% 33% 404 267 350 16% 51% 22% 16% 23% 3.57 2.37 3.05 17% 51% |
6,369 6,239 02% 1,944 2,045 -05% 31% 33% 1,340 1,370 -02% 21% 22% 11.72 11.92 -02% |
CONSOLIDATED FINANCIAL REVIEW (Y-o-Y basis):
Revenue from Operations:
Revenue from operations on consolidated basis increased to ₹ 1,859 million in the Q1 FY26 from ₹ 1,545 million in the Q1 FY25, a growth of 20%.
Profit:
Consolidated EBITDA during Q1 FY26 stands at ₹ 564 million as compared to ₹ 512 million during Q1 FY25, an increase of 10%.
Margin:
EBITDA margin stands at 30%, PBT margin stands at 30% and PAT margin stands at 22% during the quarter.
Financial Costs:
Financial costs stood at ₹ 8 million during Q1 FY26 as against ₹ 9 million in Q1 FY25.
Depreciation and Amortization:
Profit before tax stands at ₹ 549 million during Q1 FY26 as against ₹ 487 million in Q1 FY25, an increase of 13%.
Profit after tax grew by 16% and stands at ₹ 404 million during Q1 FY26 as compared to ₹ 350 million during the Q1 FY25.
Depreciation and Amortization charge for the Q1 FY26 stood at ₹ 96 million as compared to ₹ 86 million in the same quarter previous year.
Earnings Per Share:
Earnings Per Share during Q1 FY26 stands at ₹ 3.57 as compared to ₹ 3.05 in Q1 FY25.
www.advancedenzymes.com 1
==> picture [135 x 35] intentionally omitted <==
OPERATIONAL PERFORMANCE REVIEW:
Segmental Revenue:
| (Amount in INR Mn.) | Q1 FY26 Q1 FY25 Change (%) |
|---|---|
| Human Nutrition Animal Nutrition Bio-Processing Specialized Manufacturing |
1,221 1,012 21% 260 172 51% 236 251-06% 142 110 29% |
==> picture [202 x 174] intentionally omitted <==
----- Start of picture text -----
7%
Human Nutrition
13%
Animal Nutrition
14% Bio-Processing
66% Specialized
Manufacturing
----- End of picture text -----
The total revenue from operations grew by 20% on y-o-y basis and 11% on q-o-q basis.
The revenue from human nutrition segment increased by 21% to ₹ 1,221 million in Q1 FY26 as compared to ₹ 1,012 million in Q1 FY25. This growth is on account of robust sales in Pharma/API business.
The Animal nutrition delivered a growth of 51% to ₹ 260 million in Q1 FY26 as against ₹ 172 million in Q1 FY25.
The Bio-Processing segment declined by 6% during the quarter, it accounted for ₹ 236 million in Q1 FY26 as compared to ₹ 251 million in Q1 FY25. In this segment, food business de-grew by 11% to ₹ 174 million on y-o-y basis during Q1 FY26. The Non-Food business grew by 11% to stood at ₹ 62 million during the quarter.
The Specialized manufacturing segment contributed 7% in the pie which is around ₹ 142 million to the revenue during the quarter, higher by 29% on y-o-y basis.
Geographical Revenue:
==> picture [250 x 146] intentionally omitted <==
----- Start of picture text -----
3%
9%
5% India
Americas
53% Europe
Asia (ex-India)
30%
Rest of the world
----- End of picture text -----
Domestic sales accounted for ₹ 979 million in Q1 FY26 as compared to ₹ 740 million in Q1 FY25, higher by 32%.
The total revenue comprises of International sales amounting to ₹ 881 million in Q1 FY26 as compared to ₹ 806 million in Q1 FY25, an increase of 9%. The revenue declined by 4% in Americas while registered a growth of 23% in Europe, 59% in Asia (ex-India) and 61% in the rest of the world.
The domestic sales constituted about 53% of revenue from operations during Q1 FY26 as compared to 48% during Q1 FY25. International sales were 47% of revenue from operations during Q1 FY26 as compared to 52% during Q1 FY25.
www.advancedenzymes.com 2
==> picture [135 x 35] intentionally omitted <==
CONSOLIDATED FINANCIAL REVIEW (Q-o-Q basis):
Revenue from Operations:
Revenue from operations on consolidated basis increased to ₹ 1,859 million in the Q1 FY26 from ₹ 1,672 million in the Q4 FY25, a growth of 11%.
₹ 267 million during the Q4 FY25.
Financial Costs:
Financial costs remain unchanged and stood at ₹ 8 million during Q1 FY26 to the last quarter.
Profit:
Consolidated EBITDA during Q1 FY26 stands at ₹ 564 million as compared to ₹ 456 million during Q4 FY25, higher by 24%.
Profit before tax stands at ₹ 549 million during Q1 FY26 as against ₹ 435 million in Q4 FY25, an increase of 26%
Depreciation and Amortization:
Depreciation and Amortization charge for the Q1 FY26 is ₹ 96 million as compared to ₹ 101 million in the last quarter.
Earnings Per Share:
Earnings Per Share during Q1 FY26 stands at ₹ 3.57 as compared to ₹ 2.37 in Q4 FY25.
Profit after tax grew by 51% and stands at ₹ 404 million during Q1 FY26 as compared to
OPERATIONAL PERFORMANCE REVIEW:
Segmental Revenue:
| (Amount in INR Mn.) | Q1 FY26 Q4 FY25 Change (%) |
|---|---|
| Human Nutrition Animal Nutrition Bio-Processing Specialized Manufacturing |
1,221 1,031+19% 260 209+24% 236 278-15% 142 154-08% |
The human nutrition segment reflected a growth 19% to ₹ 1,221 million in Q1 FY26 as compared to ₹ 1,031 million in Q4 FY25.
The Animal nutrition grew by 24% to ₹ 260 million in Q1 FY26 as against ₹ 209 million in Q4 FY25.
The Bio-Processing segment underperformed by 15% during the quarter, it accounted for ₹ 236 million in Q1 FY26 as compared to ₹ 278 million in Q4 FY25. In this segment, the food business degrew by 24% to ₹ 174 million, while non-food grew by 28% to ₹ 62 million respectively, during the quarter in comparison to Q4 FY25.
The Specialized manufacturing segment saw a decline of 8% to ₹ 142 million in Q1 FY26 from ₹ 154 million in Q4 FY25.
Geographical Revenue:
Domestic sales accounted for ₹ 979 million in Q1 FY26 as compared to ₹ 704 million in Q4 FY25, a growth of 39%. The domestic sales constituted about 53% of revenue from operations during Q1 FY26 as compared to 42% during Q4 FY25.
The total revenue comprises of International sales amounting to ₹ 881 million in Q1 FY26 as compared to ₹ 968 million in Q4 FY25, decline of
9%. The revenue de-grew by 13% in Americas, 10% in Europe and 2% in Asia (ex-India) while registered a growth of 19% in rest of the world.
International sales were 47% of revenue from operations during Q1 FY26 as compared to 58% during Q4 FY25.
www.advancedenzymes.com 3
==> picture [135 x 35] intentionally omitted <==
OUTLOOK 2025-26
Advanced Enzymes remains committed to enhancing and strengthening its business model by maintaining a strong focus across its three key segments—Human Nutrition, Animal Nutrition, and Bio-Processing. The company is actively working on expanding its product portfolio, particularly in the probiotics space, through ongoing development and new product launches. With its current infrastructure and capital investments, Advanced Enzymes is wellpositioned to grow its enzymes and probiotics business.
Human Nutrition:
The Company already operates a successful B2C business in the USA and is now replicating this model in India to drive growth and explore new opportunities. It remains committed to expanding its B2C presence within the Human Nutrition sector. As part of this strategy, the Company has launched its own nutraceutical brand, Wellfa, targeting to Indian consumers. The brand offers a wide range of products, including immune support, skincare, gut health, metabolism enhancement, detox solutions, weight management, stress relief, and respiratory health, among others.
This segment is expected to become a key growth driver for the Company. Additionally, it is selling through other online platforms to diversify and strengthen its digital sales channels.
Nutrition segment, it is committed to launching new products aimed at boosting immunity, improving digestion, and enhancing the nutritional value of animal feed.
Bio Catalysis:
The Company has achieved notable progress in developing biocatalysis for API manufacturers, offering targeted enzymatic solutions that help reduce energy consumption, processing time, and chemical usage. Some of these products are at various stages of development, with a few currently in advanced plant-level trials with API manufacturers. This area represents a key opportunity where the Company intends to maintain its focus and ongoing efforts.
Baking:
The Company offers a diverse portfolio of enzymes for the food processing sector and has submitted 15 dossiers to the European Food Safety Authority (EFSA), receiving positive opinions for 9 of them. Its product range demonstrates efficacy and performance on par with leading industry players. With a strong focus on value-driven solutions, the Company is well-positioned to expand its presence across Europe, the Americas, and other global markets, particularly within the baking industry.
Research & Development:
Animal Nutrition:
In the Animal Nutrition segment, the Company is actively carrying out trials and research to develop innovative and more effective nutritional products aimed at enhancing the performance of animal feeds. Efforts are underway to register and launch additional products in both domestic and international markets. Simultaneously, the Company plans to expand its sales and marketing teams across the USA, MENA, and Asian regions, while also aiming to broaden its global presence by appointing new distributors in international markets.
Probiotics:
The Company continuously make efforts on introducing additional probiotic products in the Human Nutrition segment, focusing on immunity enhancement, active health foods, gut health, and various nutraceutical applications. In the Animal
The Company is making substantial investments in state-of-the-art R&D infrastructure, aiming to lead innovation in the formulation of new applications. With a strong focus on expanding its application portfolio across various industries, the Company remains committed to ongoing R&D investment. It also plans to further strengthen its R&D team to support this growth and drive future advancements.
Inorganic expansion:
The Company has a strong track record of inorganic growth, having successfully completed four acquisitions over the past nine years, all financed through internal accruals, maintaining its status as a zero-debt entity. It will continue to explore strategic acquisition opportunities that can enhance its frontend marketing capabilities, expand its geographical footprint, strengthen its product portfolio, and bolster its B2C business.
www.advancedenzymes.com 4
==> picture [135 x 35] intentionally omitted <==
RESULTS CONFERENCE CALL DETAILS
Advanced Enzymes will hold an earnings conference call on 06[th] August 2025, Wednesday at 16:00 Hours IST to discuss quarterly performance. The transcript of the call will be available later in the Investor Relations section on the Company’s website, www.advancedenzymes.com
Please dial the numbers at least 5-10 minutes prior to the conference schedule to ensure that you are connected on time.
Conference Call Primary Number: +91 22 6280 1403 / +91 22 7115 8304
Pre-registration link
For further information, please contact:
Ronak Saraf
Investor Relations [email protected]
CORPORATE INFORMATION :
Advanced Enzyme Technologies Limited Regd. Office: 5[th] Floor, ‘A’ Wing, Sun Magnetica, Louiswadi, Thane (W) ‐400 604, Maharashtra, India Tel.: +91 22 41703200 Fax: +91-22 25835159 Website: www.advancedenzymes.com CIN No: L24200MH1989PLC051018
www.advancedenzymes.com 5